|
(V150) |
Combined Feature Tracking and T2 mapping reliably distinguishes athletes heart from pathologic left ventricular hypertrophy |
| |
|
M. Gastl, V. Lachmann, S. M. Haberkorn, P. Behm, N. Janzarik, L. Holzbach, V. Veulemans, C. Jacoby, B. Schnackenburg, T. Zeus, M. Kelm, F. Bönner (Düsseldorf, Hamburg) |
|
|
Diskussion |
|
(V151) |
Long-term results of percutaneous septal ablation for hypertrophic obstructive cardiomyopathy (HOCM): Do younger patients have a less favourite outcome? |
| |
|
L. Faber, Z. Dimitriadis, H. Seggewiß, F. van Buuren, D. Horstkotte (Bad Oeynhausen, Schweinfurt) |
|
|
Diskussion |
|
(V152) |
Is LV Hypertrophy in Hypertrophic Cardiomyopathy Static? 5-year Follow Up by Cardiac Magnetic Resonance Imaging in Adolescents and Adults. |
| |
|
M. Ochs, S. Buß, H. A. Katus, M. Friedrich (Heidelberg) |
|
|
Diskussion |
|
(V153) |
Risikoprädiktion ventrikulärer Tachyarrhythmien und adäquater ICD-Therapie bei Patienten mit hypertropher Kardiomyopathie |
| |
|
L. Dinshaw, J. Münch, J. Dickow, S. Willems, M. Patten-Hamel, B. A. Hoffmann (Hamburg) |
|
|
Diskussion |
|
(V154) |
Hypertrophic cardiomyopathy patients are characterized by a reduced myocardial perfusion reserve as shown by CMR-based coronary sinus flow measurements |
| |
|
A. R. Florian, M. Bietenbeck, Z. Shomanova, B. Mannefeld, A. Yilmaz (Münster) |
|
|
Diskussion |
|
(V155) |
High incidence and evidence of causal relationship between chronic hepatitis C virus infection and cardiac dysfunction |
| |
|
W. Poller, Z. Kaya, C. Skurk, M. Kasner, M. Muche, K. Kappert, R. Tauber, F. Escher, H.-P. Schultheiss, H.-J. Epple, U. Landmesser (Berlin, Heidelberg) |
|
|
Diskussion |